Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Schering-Plough's Nasonex

This article was originally published in The Tan Sheet

Executive Summary

Schering-Plough's Nasonex: NDA filed Sept. 30 for the prescription mometasone furoate aqueous nasal spray. Schering is seeking use of the once-daily Nasonex for "prophylaxis and treatment of symptoms of seasonal allergic rhinitis and the treatment of perennial rhinitis in adults and adolescents 12 years of age and older," the company reports. Mometasone furoate also is being developed in dry powder and metered-dose inhaler formulations for bronchial asthma...
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086197

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel